Pfizer is resisting Novo Nordisk's Metsera offer.

Pfizer Inc. (NYSE: PFE) is aware that the acquisition proposal made by Novo Nordisk A/S (NYSE: NVO) for Metsera, Inc. (NASDAQ: MTSR) is a concerning and unprecedented initiative. This proposal is an attempt by a dominant player in the market to unlawfully suppress competition with a new American competitor. It is also stated that the proposal is structured to circumvent antitrust laws and carries significant regulatory and enforcement risks.

Pfizer asserts that under its agreement with Metsera, this proposal cannot be characterized as a legitimate superior offer and is prepared to pursue all legal avenues to protect its rights.

According to statements in Metsera's proxy documents, the Metsera Board of Directors previously rejected Novo Nordisk’s offer due to "various risks" in the deal structure. The Board chose Pfizer among other bidders because none of the other bidders could offer the same level of assurance in completing the acquisition of Metsera’s 100% share in the expected timeframe. The Pfizer agreement creates real, definite, and immediate value for Metsera’s shareholders and positions Metsera’s significant drug candidate to emerge as a major competitor in this critical therapeutic area accessible to all Americans.

Investors are advised to carefully evaluate the aforementioned factors and other risks and uncertainties that may affect Pfizer's business. This information is detailed in Pfizer's Annual Report in the sections "Risk Factors" and "Forward-Looking Information and Factors That Could Affect Future Results".

Investors are cautioned not to place undue reliance on these forward-looking statements, and Pfizer undertakes no obligation to update or revise these disclosures.